Mathilde/NLI4PR huggingface dataset:
Patient case (clinical description): A 40-year-old woman comes to the clinic complaining of gritty sensation in her eyes. She also has difficulty swallowing dry foods with no pain or heartburn.  The patient is a schoolteacher and must drink water frequently during lectures due to her mouth dryness.  She also reports occasional joint pain.  Medical history is not significant other than the confirmed Sjogren disease with no other rheumatologic disease.  She is sexually active with her husband and has 2 children both delivered by natural vaginal delivery. She has no history of any kind of surgery. Physical examination shows conjunctival erythema and cracking of the lips. The remainder of the examination and history is normal. Her lab result shows elevated ESR (50 mm/h)

Patient's own account: I went to the clinic because I had a terrible gritty sensation in my eyes. It was also hard to swallow dry food, but it didn't burn, and there was no pain. I'm a 40-year-old female school teacher and I should drink water for the lectures because otherwise, my mouth gets really dry. I also have joint pain from time to time. I have been diagnosed with Sjogren disease but no other rheumatologic disease. I have a husband, we're sexually active, and I also have two lovely children that I delivered both naturally. I never undergone any surgery. Physical examination when I came to the clinic, and it showed cracking on my lips and a pink eye. The rest was fine. I also did some lab tests, and they came back with high ESR.

Clinical trial: A Study of Flt3-Ligand Levels in Sjögrens Syndrome

Eligibility criteria:
Inclusion Criteria:

          -  fulfill the ACR-criteria for primary Sjogrens syndrome,

          -  age above 18 years old

        Exclusion Criteria:

          -  other CNS-disease
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 20-year-old man comes to the clinic for his routine checkup. The patient wears glasses for myopia and takes no medications.  Vital signs are normal.  On physical examination, the patient is tall with long upper extremities and fingers.  The face appears narrow with down-slanted palpebral fissures, flattened malar bones, and a small jaw.  The lungs are clear on auscultation.  The abdomen is soft with no organomegaly. The patient is diagnosed with Marfan syndrome, and he is cooperative with his medical appointments. He is working as driver.

Patient's own account: I'm a 20-year-old guy, working as a driver and I went to the clinic for my routine checkup. I have myopia, so I wear glasses and I don't take any other medications. My vitals were normal. I also did a physical exam, and I was told that I have long legs, arms, and fingers. They also told me that my face is quite narrow, with down-slanted eyes and a small jaw. My lungs were fine and my tummy too. I have been diagnosed with Marfan syndrome and I haven't been skipping any medical appointments since.

Clinical trial: Vaccination for Middle Ear Infection

Eligibility criteria:
Healthy volunteers between ages 18 and 35 years.

        Not pregnant or planning to become pregnant in next six months.

        HIV negative.

        Hepatitis B Negative.

        No chronic Respiratory Tract Infections.

        No history of abnormal immune system.

        No severe or multiple allergies.
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers



Eligibility (NLI label): Entailment
Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

Eligibility criteria:
Inclusion Criteria:

          -  At least 18 years old

          -  Confirmed SARS-CoV-2 viral infection

          -  Advanced COVID-19 with score of 3 or 4 on NIAID scale (first 40 patients) or score of
             3 on NIAID scale (last 40 patient

          -  Has at least one of the following: fever, cough, sore throat, malaise, headache,
             muscle pain, shortness of breath, confusion or severe lower respiratory symptoms

          -  Off antiviral medications at least 24 hours prior to first dose of study drug (except
             for remdesivir)

          -  Able to provide consent

          -  Agree to appropriate methods of contraception

        Exclusion Criteria:

          -  In critical condition or has ARDS

          -  On invasive mechanical ventilation or ECMO

          -  Bacterial or fungal infection

          -  Pregnant or lactating (women)

          -  ALT >5x ULN, bilirubin >2x ULN, INR outside of normal limits at screening

          -  eGFR <30 mL/min

          -  Clinically relevant serious co-morbid medical conditions

          -  Treatment with any immunosuppressive therapy within 30 days prior to screening

          -  Treatment with another investigational drug within 30 days or 5 half-lives of drug
             prior to screening

          -  Prior treatment with the study drug (MMPD) or treatment with remdesivir more than 24
             hours prior to the first randomized dose of study drug

          -  Known hypersensitivity to the inactive ingredients in the study drug (MMPD or placebo)
             or any ingredient of remdesivir
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

Eligibility criteria:
Inclusion Criteria:

          1. Males ≥ 18 years of age with hemophilia A and documented prior residual FVIII activity
             ≤ 1 IU/dL including, but not limited to, at the time of detected inhibitors, at the
             time of signing the informed consent.

          2. History of a positive inhibitor result with the first positive result in the last 12
             months.

             Part A: Positive FVIII inhibitor titer ≥ 0.6 BU. Part B: Negative FVIII inhibitor
             screening titer < 0.6 BU.

          3. Part A: Emicizumab prophylaxis at least 6 months prior to screening; Part B: FVIII
             replacement prophylaxis for 12 months. Bleeding, inhibitor & hemophilia therapy Hx
             over previous 12 months.

          4. Sexually active participants must agree to use an acceptable method of effective
             contraception. Participants must agree to contraception use for at least 12 weeks
             post-infusion.

          5. Willing to abstain from consumption of alcohol for at least the first 52 weeks
             following BMN 270 infusion.

        Exclusion Criteria:

          1. Detectable pre-existing antibodies to the AAV5 capsid.

          2. Any evidence of active infection or any immunosuppressive disorder, including HIV
             infection.

          3. Currently undergoing, or plan to receive during the study, immune tolerance induction
             therapy or prophylaxis with FVIII (Part A only).

          4. Significant renal dysfunction or liver dysfunction, infection or history of hepatic
             malignancy.

          5. Evidence of any bleeding disorder not related to hemophilia A.
Male
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Contradiction
Patient case (clinical description): A 9-year-old girl is brought to the office for evaluation of short stature and overweight body habitus. The patient's mother and father are 170 cm and 181 cm tall, respectively.  On physical examination, the patient's height is in the 5th percentile of her age.  Other findings include low-set ears, a high arched palate, a webbed neck, and cubitus valgus.  Chromosomal analysis reveals a 45, XO karyotype.

Patient's own account: I took my 9-year-old daughter to the doctor because my mother-in-law kept saying she seemed small and overweight. My husband and I are 170 cm and 181 cm tall, respectively. The physical health highlighted that she is in the 5th percentile of her age. The doctor said that she has low-set ears, a high-arched palate, a webbed neck, and cubitus valgus. She also did a chromosomal analysis, which revealed a 45, XO karyotype.

Clinical trial: The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.

Eligibility criteria:
Inclusion Criteria:

          -  Bone age < 10 years female, < 12 years male

          -  Pubertal status: Girls: Tanner I for breast development. Boys: testicular volume of ≤
             3 cc, as measured by the standardized orchidometer (Prader type). The onset of pubic
             hair development up to and including Tanner III is allowed in the study.

          -  Adequate nutrition: body mass index ≥ 25th percentile for gender.

        Exclusion Criteria:

          -  Syndromic short stature

          -  Chronic illnesses.

          -  Other disorders, including osteo- or chondrodystrophies, and endocrine causes of short
             stature such as Cushing syndrome, and untreated hypothyroidism.
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 4 Years old.
Subject must be at most 12 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 47-year-old man comes to the office due to weight gain and fatigue.  He is not able to lift heavy objects or climb stairs. Family history is positive for DM type 2 and HTN in his father.  Blood pressure is 165/90 mm Hg and pulse is 85/min.  On physical examination, there is symmetric proximal muscle weakness of the upper and lower extremities.  Fasting plasma glucose level is 138 mg/dL and 24-hour urinary cortisol is twice the upper normal limit.  Further evaluation reveals that high-dose, but not low-dose, dexamethasone suppresses serum cortisol levels.  Serum ACTH levels are high-normal. This patient's findings are consistent with endogenous Cushing Syndrome.

Patient's own account: I'm a 47-year-old man. I went to the clinic because I had been gaining weight and had increased fatigue over the past few weeks. I was not able to lift heavy objects or even climb the stairs. My dad was diagnosed with type 2 diabetes and high blood pressure. During the exam, they took my blood pressure, which was 165/90 mm Hg, and my pulse was 85/min. They found out that I have weaknesses in both of my arms and legs. I also did a blood test on an empty stomach, and I had a glucose level of 138 mg/dL, and twice the upper normal limit of cortisol. I had high-normal levels of ACTH. The doctor said I suffer from endogenous Cushing Syndrome.

Clinical trial: Cognition, Steroids, and Imaging in Cushings Disease

Eligibility criteria:
Inclusion criteria:

          -  patients with suspected Cushing's syndrome with clinical findings suggestive of
             Cushing's syndrome and positive screening tests (urinary free cortisol and low dose
             overnight dexamethasone suppression test).

        Exclusion criteria: none
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 9 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): An 8-year-old boy is brought to the clinic by his parents because of weakness and difficulty of standing up from a sitting position. The mother is healthy but had a brother who died in his 20th after being disabled and using wheelchairs in the last few years of his life. Physical examination shows 3/5 lower extremity muscle strength and enlarged calf muscles. The other physical examination and vital signs are unremarkable. Muscle biopsy showed absence of dystrophin protein. The patient is diagnosed with DMD.

Patient's own account: I brought my  8-year-old son to the doctor's clinic. He was struggling to stand up from a chair for the past few days. My wife is healthy but she was pretty worried since his brother died in his 20s after being disabled and using a wheelchair for the last years of his life. The doctor did an exam which highlighted weakness in the leg muscles and unusually large calf muscles. The rest of the exam was fine, and his vitals were normal. My son did a muscle biopsy, and it showed that the protein important for muscle strength and function is missing. The doctor diagnosed him with Duchenne muscular dystrophy.

Clinical trial: Duchenne Muscular Dystrophy Heart Study

Eligibility criteria:
Inclusion Criteria:

          -  Genetically-proven Duchenne Muscular Dystrophy (DMD mutation)

          -  Covering by social security

        Exclusion Criteria:

          -  Patient refusal to participate to the study
Male
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Entailment
Patient case (clinical description): A 4-year-old boy comes to the office for the follow up of his confirmed oculocutaneous albinism.  The patient was born at 38 weeks gestation with no complications.  Vital signs are normal.  Weight and height are at the 50th percentile.  On examination, iris transillumination is present, and there are no apparent foveae on funduscopic examination.  Optic nerves are small and gray.  All the hairs including eyebrows and lashes are white.

Patient's own account: I brought my four-year-old son to his follow-up consultation for his albinism. All his hair is white, even lashes and eyebrows. My baby was born at 38 weeks pregnant with no complications whatsoever. During the consultations his vitals were normal and now his weight and height are at the 50th percentile. The doctor did an eye exam and it seems that his iris has a kind of transillumination, and there are no foveae. The doctor told me that his optic nerves are small and gray.

Clinical trial: Study of Chediak-Higashi Syndrome

Eligibility criteria:
-  ELIGIBILITY:

        Patients will be between the age of 1 month and 70 years. All patients entering this study
        will have some degree of oculocutaneous albinism plus either a bleeding diathesis or a
        history of excessive infections in childhood. Objective evidence of a platelet storage pool
        deficiency (e.g., an abnormal secondary aggregation response or absent platelet dense
        bodies) or of a lysosomal fusion abnormality (e.g., giant cytoplasmic granules in
        leucocytes) will not be required.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 1 Month old.
Subject must be at most 70 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Role of Vagal Tone in Rumination Syndrome

Eligibility criteria:
Inclusion Criteria:

          1. Healthy volunteers (HVs)

               -  18-65 years old

               -  No history of any gastrointestinal (GI) symptoms in the 3 months prior to the
                  study.

               -  No medications 3 months prior to the study

          2. Rumination patients

               -  18-65 years old

               -  Fulfilling ROME IV clinical criteria for rumination

               -  Confirmed rumination syndrome by High Resolution Impedance Monometry within 12
                  months prior to the study

               -  No history of performing DiaB as a therapy for rumination syndrome.

               -  No medications which may affect vagal tone, the number of rumination episodes and
                  GI motility 3 months prior to the study. (i.e. opioids, Baclofen ,
                  anticholinergics drugs, prokinetics, beta-blockers)

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  History of GI surgeries apart from appendectomy

          -  Alcohol or substance abuse, mental health illness

          -  Inability to obtain informed consent

          -  Non-fluent English speakers

          -  Participants with food intolerances or allergies that would not be able to take in the
             test meal (McDonalds Big Mac meal)

          -  Major comorbidities such as significant cardiac/pulmonary disease, cancer,
             life-threatening conditions or other life-limiting conditions

          -  Evidence of relevant organic diseases. (in endoscopy, CT.)

          -  Evidence of major esophageal motility disorders (Chicago classification ver3.0) (21)

          -  Known allergy to ECG electrodes or latex

          -  History of diabetes
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.
Subject must be at most 65 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: SSRI Study for Functional Dyspepsia (SS)

Eligibility criteria:
Inclusion Criteria:

          -  • Patients with functional dyspepsia that fulfill Rome III criteria

               -  Has element of anxiety or depression reported at baseline screened by HADS
                  (either subscale of HADS - HAS or HDS scores 8 or higher)

               -  Age 18-60

               -  Provision of written consent

               -  No evidence of structural disease (including at upper endoscopy) that is likely
                  to explain the dyspeptic symptoms

        Exclusion Criteria:

          -  • Diabetes mellitus

               -  Organic brain syndrome

               -  Moderate or severe Depression diagnosed by Structured Clinical Interview for
                  DSM-IV conducted by a psychiatrist or trained research staff

               -  History of psychosis, bipolar disorder or substance abuse/dependence

               -  On psychiatric medication (SSRI, SNRI, tricyclic antidepressants, anxiolytics)

               -  Has suicidal ideation in the past two weeks as screened by PHQ at baseline
                  assessment

               -  Diagnosis of GERD by GERDQ questionnaire (GERDQ score ≥8) included in the FGI
                  Screening Questionnaire (v.3) completed at baseline visit

               -  Concurrent medications that affect GI motility

               -  History of gastric surgery

               -  Organic disease as cause of dyspepsia

               -  H. pylori infection

               -  Use of PPI or NSAID in the past 4 weeks

               -  Pregnancy

               -  Known hypersensitivity to SSRI

               -  Unable to read Chinese or illiterate
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.
Subject must be at most 60 Years

Eligibility (NLI label): Contradiction